241 active trials 122 recruiting 21 Phase 3 165 sponsors 33 changes in 30 days
| Early Phase 1 | 4 | |
| Phase 1 | 22 | |
| Phase 1/2 | 25 | |
| Phase 2 | 54 | |
| Phase 2/3 | 6 | |
| Phase 3 | 15 | |
| Phase 4 | 3 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07150624 | The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine | Anhui Provincial Hospital | Recruiting | 2026-05-11 |
| NCT06594744 | Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal… | Taipei Veterans General Hospital, Taiwan | Recruiting | 2025-02-13 |
| NCT06923176 | Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular… | Zhiyun Yang | Not Yet Recruiting | 2025-04-11 |
| Phase 3 | ||||
| NCT07322848 | DEB-TACE vs cTACE in HCC After TIPS | First Affiliated Hospital, Sun Yat-Sen University | Recruiting | 2026-05-01 |
| NCT07186621 | Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | 2025-09-22 |
| NCT06841172 | Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line… | Shandong Cancer Hospital and Institute | Recruiting | 2025-08-01 |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored… | Exelixis | Enrolling by Invitation | 2026-08-18 |
| NCT04523493 | Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC | Shanghai Junshi Bioscience Co., Ltd. | Active, Not Recruiting | 2026-07-06 |
| NCT05883644 | Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced… | AstraZeneca | Active, Not Recruiting | 2026-04-30 |
| NCT07537946 | Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer | Tongji Hospital | Not Yet Recruiting | 2026-04-17 |
| NCT07381660 | SBRT Versus Surgical Resection for Small HCC | Sun Yat-sen University | Not Yet Recruiting | 2026-02-02 |
| NCT05904886 | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in… | Hoffmann-La Roche | Active, Not Recruiting | 2025-12-31 |
| NCT04639180 | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in… | Jiangsu HengRui Medicine Co., Ltd. | Active, Not Recruiting | 2025-12-30 |
| NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants… | Exelixis | Active, Not Recruiting | 2025-12-11 |
| NCT06680258 | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or… | Tempest Therapeutics | Not Yet Recruiting | 2025-09-03 |
| NCT07027436 | Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus… | Hamilton Health Sciences Corporation | Not Yet Recruiting | 2025-06-18 |
| NCT06841185 | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of… | Shanghai Henlius Biotech | Not Yet Recruiting | 2025-02-24 |
| NCT04344158 | A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride… | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active, Not Recruiting | 2025-02-20 |
| Phase 2/3 | ||||
| NCT07490262 | A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy… | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Recruiting | 2026-04-16 |
| NCT07293468 | Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs… | Tuen Mun Hospital | Recruiting | 2026-04-09 |
| NCT06644937 | Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After… | Zhujiang Hospital | Recruiting | 2025-09-23 |
| NCT06109272 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of… | AbbVie | Recruiting | 2025-08-15 |
| NCT07392866 | A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the… | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Not Yet Recruiting | 2026-02-09 |
| NCT06739317 | SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with… | Sun Yat-sen University | Not Yet Recruiting | 2024-12-18 |
| Phase 2 | ||||
| NCT07689175 | Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma | University of Texas Southwestern Medical Center | Recruiting | 2026-08-25 |
Sun Yat-sen University (8) · Tongji Hospital (7) · Fudan University (6) · Seoul National University Hospital (6) · Nanfang Hospital, Southern Medical University (5) · Zhejiang University (5) · Shanghai Zhongshan Hospital (4) · AbbVie (3) · Anhui Provincial Hospital (3) · Assistance Publique - Hôpitaux de Paris (3)